Morgan Stanley 9 Meters Biopharma, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.21 - $0.32 $2,643 - $4,027	-12,587 Reduced 10.92%	102,678 $22,000
Q2 2022 Oct 27, 2022	BUY	$0.26 - $0.64 $4,298 - $10,580	16,532 Added 16.74%	115,265 $29,000
Q2 2022 Aug 15, 2022	BUY	$0.26 - $0.64 $4,298 - $10,580	16,532 Added 16.74%	115,265 $29,000
Q1 2022 Oct 27, 2022	SELL	$0.52 - $1.0 $8,596 - $16,532	-16,532 Reduced 14.34%	98,733 $60,000
Q1 2022 May 13, 2022	SELL	$0.52 - $1.0 $9,624 - $18,508	-18,508 Reduced 15.79%	98,733 $60,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $23,182 - $36,273	27,273 Added 30.31%	117,241 $114,000
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $92,667 - $126,854	89,968 New	89,968 $118,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.